News und Analysen
AT&T Just Made a Smart $23 Billion Bet
Telecom giant AT&T (NYSE: T) struck a deal with EchoStar on Tuesday to acquire wireless spectrum licenses that cover nearly ever market across the U.S. The company will pay $23 billion for 30 MHz of
Stock Market Today: Rally Holds as Tech and Industrials Lead Gains, Fed Changes Loom
U.S. equity markets rose broadly on Tuesday as optimism over monetary policy, upbeat corporate news, and anticipation of Nvidia (NASDAQ: NVDA)'s earnings propelled gains. The S&P 500 added 0.41%
3 Stocks That Could Double in the Next Few Years
When it comes to growth stocks, you have to understand the risks going in. But there are three growth stocks that I have strong convictions about, and they could produce huge returns for investors.
EQS-Adhoc: Bio-Gate AG: Resolves to Conduct a Capital Increase from Authorized Capital and Announces the Terms of the Rights Offering Approved by the Annual General Meeting on June 30, 2026
EQS-News: Heidelberg Pharma Reports on First Half-Year 2026 and the Positive Course of Business
EQS-News: Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2026
EQS-News: Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2026
EQS-News: Heidelberg Pharma Announces Change in Executive Board
EQS-Adhoc: Heidelberg Pharma AG: Heidelberg Pharma Determines Recommended Dose for Phase II Trial with ADC Candidate HDP-101
EQS-News: Heidelberg Pharma to Present Data from its ADC Technology Platform at AACR Annual Meeting 2026
Uni-Bio Science Group Limited Announces 2025 Annual Results
EQS-News: Heidelberg Pharma Announces Financial Figures and Reports on Business Performance in 2025 and Outlook for 2026
EQS-News: Heidelberg Pharma to Receive Milestone Payment from Partner Huadong for Clinical Study with HDP-101 in China
EQS-News: Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital
EQS-Adhoc: Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital
Form 8.3 - The Vanguard Group, Inc.: Oxford Biomedica plc
Form 8.3 - The Vanguard Group, Inc.: Oxford Biomedica plc
EQS-News: Heidelberg Pharma Received Development Milestone Payment from Partner Takeda
Sensorion Announces €60 Million Financing With a €20M Strategic Investment from Sanofi and Support from Global Healthcare Specialists To Advance Genetic Medicine Pipeline
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing
Form 8.3 - The Vanguard Group, Inc.: Oxford Biomedica plc
Sensorion to Present at the 44th Annual J.P. Morgan Healthcare Conference
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Sensorion Reports Independent Data Monitoring Committee Raises No Safety Concerns and Agrees to Continue SENS-501’s Audiogene Phase 1/2 Trial
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss
EQS-News: Heidelberg Pharma Announces Changes to the Executive Management Board – Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer
EQS-Adhoc: Heidelberg Pharma Announces Changes to the Executive Management Board - Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer